Skip to main content
. 2018 Sep 21;9:1857. doi: 10.3389/fimmu.2018.01857

Figure 3.

Figure 3

MCP-1, Mip-1α, and Mip-2α (MMM) activate MK2 signaling and downstream cytokine expression in colon cancer cells. CT26 cells treated with MMM induce (A) MK2 phosphorylation. MK2i treatment inhibits (B) IL-1β, (C) IL-6, and (D) TNF-α in tumor supernatants, but this effect is reversed upon addition of MMM when examined by multiplex cytokine array. (E) Additional mRNA data for IL-1β and TNF-α since the protein level is low support the increase in cytokine gene expression. (F) MK2 is also phosphorylated in CT26 tumors, is decreased at day 13 in tumors treated with MK2 inhibitor, and is restored by addition of MMM in tumor treated with MK2 inhibitors. N = 7–8 for tumors, * and **p ≤ 0.05.